Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Depreciation & Amortization (CF): 2014-2025

Historic Depreciation & Amortization (CF) for CytomX Therapeutics (CTMX) over the last 11 years, with Sep 2025 value amounting to $98,000.

  • CytomX Therapeutics' Depreciation & Amortization (CF) fell 75.06% to $98,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 33.16%. This contributed to the annual value of $1.6 million for FY2024, which is 20.06% down from last year.
  • According to the latest figures from Q3 2025, CytomX Therapeutics' Depreciation & Amortization (CF) is $98,000, which was down 68.39% from $310,000 recorded in Q2 2025.
  • In the past 5 years, CytomX Therapeutics' Depreciation & Amortization (CF) ranged from a high of $643,000 in Q3 2021 and a low of $98,000 during Q3 2025.
  • Over the past 3 years, CytomX Therapeutics' median Depreciation & Amortization (CF) value was $422,000 (recorded in 2024), while the average stood at $400,727.
  • As far as peak fluctuations go, CytomX Therapeutics' Depreciation & Amortization (CF) rose by 9.22% in 2021, and later crashed by 75.06% in 2025.
  • CytomX Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $639,000 in 2021, then dropped by 10.49% to $572,000 in 2022, then dropped by 21.50% to $449,000 in 2023, then dropped by 16.26% to $376,000 in 2024, then plummeted by 75.06% to $98,000 in 2025.
  • Its last three reported values are $98,000 in Q3 2025, $310,000 for Q2 2025, and $349,000 during Q1 2025.